<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01987284</url>
  </required_header>
  <id_info>
    <org_study_id>SMR-2271</org_study_id>
    <secondary_id>2013-001227-40</secondary_id>
    <nct_id>NCT01987284</nct_id>
  </id_info>
  <brief_title>SER100 in Isolated Systolic Hypertension</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Cross-over, Multi-center Study Assessing the Safety, Tolerability and Efficacy of SER100 10 mg s.c. Twice Daily for 2 Days in Patients With Isolated Systolic Hypertension Insufficiently Treated With One or More Anti-hypertensives.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Serodus ASA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Smerud Medical Research International AS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Research Council of Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Serodus ASA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Isolated Systolic Hypertension (ISH)is the dominating hypertensive disease in elderly people.
      Much attention has recently been drawn to the strong relationship between the systolic blood
      pressure and cardiovascular morbidity.

      In previous clinical studies carried out in individuals with normal blood pressure at
      baseline SER100 decreased primarily the systolic blood pressure. It is hypothesized that the
      effect on systolic blood pressure in hypertensive patients will be larger or equal to the
      fall seen in normotensive patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in systolic blood pressure</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Isolated Systolic Hypertension</condition>
  <arm_group>
    <arm_group_label>SER100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SER100 10 mg s.c. twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered s.c. twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SER100</intervention_name>
    <arm_group_label>SER100</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>SER100</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mean systolic blood pressure ≥ 150 mmHg and mean diastolic blood pressure &lt; 90 mmHg -
             as determined by daytime continuous ambulatory blood pressure measurement (ABPM)

          -  Male or female

          -  Age 50-80 years (both inclusive) at screening

          -  Patients must be on stable doses with one or more antihypertensives

          -  BMI &lt;32 kg/m2

          -  Written informed consent

        Exclusion Criteria:

          -  Acute myocardial infarction in the last 6 months before screening

          -  Stroke in the last 6 months before screening

          -  Uncompensated heart failure (NYHA Class IV)

          -  Angina pectoris with an anticipated need for administration of short-acting nitrates

          -  Known, severe sleep apnoea

          -  Abnormal laboratory values (i.e. &gt; 2 x upper normal limit) at screening

          -  Subjects working night shifts (11 PM to 7 AM)

          -  Participation in any other clinical trial with an investigational medicinal product or
             device within 1 month prior to randomisation.

          -  Subjects with upper arm circumference ≤24 cm or ≥ 42 cm.

          -  Any general condition, serious disease or current evidence of any mental or physical
             disorder or collaboration attitude (e.g. dementia, substance abuse) which, in the
             judgment of the investigator makes the subject unsuitable for enrollment, and/or may
             interfere with the study evaluations or affect subject's safety and/or may cause risk
             for poor protocol compliance

          -  Pregnant or lactating women.

          -  Female subjects of childbearing potential, or male subjects whose female partner
             (unless post-menopausal for 1 year or surgically sterile) is unwilling to use adequate
             contraceptive measures throughout the duration of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helga Gudmundsdottir, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>FinnMedi Oy/Valkeakoski District Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRST/Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweiss University Hospital</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medi3 Innlandet</name>
      <address>
        <city>Hamar</city>
        <zip>2317</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulleval University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0450</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwick Park Hospital</name>
      <address>
        <city>Harrow</city>
        <state>Middlesex</state>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brighton and Sussex University Hospital</name>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Hungary</country>
    <country>Norway</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2013</study_first_submitted>
  <study_first_submitted_qc>November 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2013</study_first_posted>
  <last_update_submitted>October 19, 2016</last_update_submitted>
  <last_update_submitted_qc>October 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

